NCM · —
AIDX (AIDX) Stock
$0.46
+0.71%
NCM: AIDX
—
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
GlobeNewswire · Jul 27, 2026
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
GlobeNewswire · Jul 23, 2026
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
GlobeNewswire · Jul 9, 2026
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
GlobeNewswire · Jun 22, 2026
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
GlobeNewswire · May 27, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held26.16%
Institutions Held2.73%
Institutions Float Held3.69%
Peer Comparison
About AIDX
AIDX is led by CEO Jonathan Cohen, employs 13 people, headquartered in US, publicly traded since 2023.
AIDX stock trades at $0.46 with a market capitalization of $2.57M. The stock is valued at a price-to-earnings (P/E) ratio of -1.09, price-to-book of 1.71, price-to-sales of 2.65. Over the past 52 weeks the stock has ranged between $0.45 and $50.00, and currently trades 99.1% below its 52-week high.
On profitability, AIDX generates a return on equity (ROE) of 79.00% — well above the market average, a sign of a high-quality business, return on capital employed of -97.92%, an operating margin of -162.89%, a net profit margin of -328.96%.